2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2911

Tubulointerstitial Involvement in Lupus Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2842

Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2225

Twitter and Rheumatology: Significant and Incremental Growth in Usage

Education Poster II

9:00AM-11:00AM: Abstract Number: 2872

Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2874

Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 3017

TYK2 and Systemic Sclerosis Susceptibility: a New Associated Locus in the IL-12 Pathway

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2591

Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2324

Understanding the Importance of a Patient’s Role in the Management of RA: Results from a Patient-Based Survey

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2342

Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2905

Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2484

Use of Lean Six Sigma Methodology to Improve Time to Scheduling for New Patient Referrals to Rheumatology

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2365

Use of Long Term Subscutaneous Immunoglobulins in Inflammatory Myopathies: A Retrospective Analysis of 19 Patients

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2415

Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2950

Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2440

Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].